

press release

Novo Nordisk UK prepared for Brexit outcomes

Gatwick, 14 December 2020

At Novo Nordisk our first commitment is to ensure that patients treated with our medicines are able to access them, regardless of the outcome of Brexit.

We have robust plans in place to ensure a strong continuation of supply to bring our essential, lifesaving, medicines into the UK. Novo Nordisk has high stock levels in the UK, to continue to ensure patients get access to the medicines and treatments they need, as well as supporting our clinical trials. We encourage healthcare professionals to prescribe at a normal rate to allow us to plan our stock levels and to distribute our medicines and treatments in our normal way.

Throughout the COVID-19 pandemic we have worked successfully with Government, NHS England and charities to ensure that the supply of medicines has remained consistent with the needs of patients and the NHS. The UK has benefitted through this period from having heightened Novo Nordisk medicines stocks in the country due to Brexit preparation.

Pinder Sahota, Corporate Vice President of Novo Nordisk UK said, "Disease does not recognise, nor is hampered by, borders. Patients in the UK should not face issues accessing their existing medicines, irrespective of the outcomes of Brexit. Nor should they face delays in access to new and innovative medicines due to changes in the regulatory process. Novo Nordisk's purpose to defeat diabetes and other serious conditions is more important than ever before, and we will not tire in ensuring that the needs of the patients we serve are met."

Novo Nordisk supplies over half of the UK's insulins, which are used by over half a million people in the UK. We have been focused on our Brexit preparations for the past five years, ensuring we have elevated stock levels in the UK and identifying additional freight routes, should they be required.

-END-

About Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 44,000

people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.co.uk

Further information

For further information, please contact:

Juliet Scott

+44 (0)7557 490 116

zjls@novonordisk.com

90ten

+44 (0) 1403 286 480

PRnovonordiskUK@90ten.co.uk